BACE1 and Alzheimer disease: Natural products-based BACE1 inhibitors with a low molecular weight (<700 Da) and high lipophilicity could easily cross the blood brain barrier and plasma membrane and reach the site of action (brain), following oral or transdermal administration [10,11], indicating their therapeutic potential for the treatment of AD.